LLY

Eli Lilly and Company

LLY, USA

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd; Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease, as well as Strategic partnership with NVIDIA Corporation. The company also has a research collaboration agreement with Insilico Medicine for the development of advance therapies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

https://www.lilly.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

1.5

Next Payout:

Dec 10, 2025

Yield:

0.5849 %
LLY
stock
LLY

My Top 3 Healthcare Stocks to Buy in 2026 The Globe and Mail

Read more →
LLY
stock
LLY

Eli Lilly (LLY): Assessing Valuation After Another Strong Share Price Run Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$1024.0007

Analyst Picks

Strong Buy

16

Buy

7

Hold

4

Sell

1

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

52.64

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

38.75

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

23.46 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Low

4.86 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

48.93 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

3.83

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 79.34% of the total shares of Eli Lilly and Company

1.

Lilly Endowment Inc

(10.7107%)

since

2025/06/30

2.

Vanguard Group Inc

(8.9695%)

since

2025/06/30

3.

BlackRock Inc

(7.358%)

since

2025/06/30

4.

PNC Financial Services Group Inc

(5.7219%)

since

2025/06/30

5.

State Street Corp

(3.8493%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(2.99%)

since

2025/07/31

7.

FMR Inc

(2.859%)

since

2025/06/30

8.

Capital Research Global Investors

(2.3154%)

since

2025/06/30

9.

Vanguard 500 Index Investor

(2.1721%)

since

2025/07/31

10.

Geode Capital Management, LLC

(2.0223%)

since

2025/06/30

11.

Capital World Investors

(1.9671%)

since

2025/06/30

12.

T. Rowe Price Associates, Inc.

(1.8791%)

since

2025/06/30

13.

Morgan Stanley - Brokerage Accounts

(1.6586%)

since

2025/06/30

14.

Wellington Management Company LLP

(1.5605%)

since

2025/06/30

15.

State Farm Mutual Automobile Ins Co

(1.3959%)

since

2025/06/30

16.

JPMorgan Chase & Co

(1.3956%)

since

2025/06/30

17.

PRIMECAP Management Company

(1.3559%)

since

2025/06/30

18.

Laurel Wealth Advisors, LLC

(1.2887%)

since

2025/06/30

19.

NORGES BANK

(1.2632%)

since

2025/06/30

20.

Bank of America Corp

(1.2564%)

since

2025/06/30

21.

Capital Group Growth Fnd of Amer Comp

(1.2426%)

since

2025/06/30

22.

American Funds Growth Fund of Amer A

(1.2426%)

since

2025/06/30

23.

Fidelity 500 Index

(1.1123%)

since

2025/07/31

24.

SPDR® S&P 500® ETF

(1.06%)

since

2025/08/31

25.

iShares Core S&P 500 ETF

(1.0559%)

since

2025/08/31

26.

Capital Research & Mgmt Co - Division 3

(1.051%)

since

2025/06/30

27.

Northern Trust Corp

(1.005%)

since

2025/06/30

28.

Vanguard Growth Index Investor

(0.984%)

since

2025/07/31

29.

Vanguard PRIMECAP Inv

(0.826%)

since

2025/06/30

30.

The Health Care Select Sector SPDR® ETF

(0.5992%)

since

2025/08/31

31.

Capital Group Investment Co of Amer Comp

(0.5985%)

since

2025/06/30

32.

American Funds Invmt Co of Amer A

(0.5985%)

since

2025/06/30

33.

American Funds Washington Mutual A

(0.5531%)

since

2025/06/30

34.

Capital Group Wash Mutual Invtrs Comp

(0.5531%)

since

2025/06/30

35.

Vanguard Health Care Inv

(0.5348%)

since

2025/06/30

36.

Vanguard Institutional Index I

(0.5305%)

since

2025/07/31

37.

Vanguard Dividend Appreciation ETF

(0.4715%)

since

2025/07/31

38.

State St S&P 500® Indx SL Cl III

(0.4684%)

since

2025/08/31

39.

Fidelity Contrafund

(0.4402%)

since

2025/07/31

40.

Loomis Sayles Long Corp Disc Alpha

(0.423%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

7.05

Latest Release

Date

2025-09-30

EPS Actual

7.02

EPS Estimate

6.37

EPS Difference

0.65

Surprise Percent

10.2041%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7.5)
Dividend
Decent Dividend Payer(4)
Economic Moat
Wide Moat Company(9.5)
GARP
Fair GARP(5)
Growth
Moderate Growth(5)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(8.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.